Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (21 quarters reported)
$1.14B in Q3 2021 → $762M now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Protagonist Therapeutics Inc | 45.3% | Unchanged | 2,449,183 | $345M |
| N Nanobiotix | 23.0% | Unchanged | 5,623,816 | $175M |
| MH Meiragtx Hldgs PLC | 9.6% | Unchanged | 6,641,064 | $73.1M |
| Rapport Therapeutics Inc | 7.9% | Unchanged | 1,784,517 | $60M |
| Contineum Therapeutics Inc | 3.5% | Unchanged | 1,979,173 | $26.6M |
| Cerebras Systems Inc | 3.0% | Added 140% | 128,649 | $22.9M |
| Xencor Inc | 2.5% | Unchanged | 748,062 | $18.7M |
| Legend Biotech Corp | 2.1% | Unchanged | 814,586 | $16.2M |
| Fate Therapeutics Inc | 1.1% | Unchanged | 3,379,064 | $8.01M |
| Cvrx Inc | 0.9% | Unchanged | 4,024,861 | $7.04M |
| Procept Biorobotics Corp | 0.9% | Unchanged | 357,939 | $6.52M |
| Neumora Therapeutics Inc. | 0.1% | Unchanged | 1,849,445 | $1.1M |
| Vor Biopharma Inc | 0.1% | Unchanged | 53,732 | $1.03M |
| Standard Biotools Inc | 0.0% | Unchanged | 311,967 | $231K |
| Adicet Bio Inc | 0.0% | Unchanged | 22,779 | $163K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2026 · filed October 26, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cerebras Systems Inc | Added | +75,063 | +$13.3M | 3.0% |
quarter ended June 30, 2026 · filed August 06, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cerebras Systems Inc | New | +53,586 | +$11.8M | 1.5% |
| Rallybio Corporation | Exited | −152,901 | −$1.37M | — |
| Nano-x Imaging Ltd. | Exited | −83,554 | −$190K | — |
quarter ended March 31, 2026 · filed May 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rallybio Corporation | Exited | −3,636,363 | −$2.49M | — |
| Lyell Immunopharma, Inc. | Exited | −54,887 | −$1.69M | — |
| Rallybio Corporation | New | +152,901 | +$1.37M | 0.2% |
| Nano-x Imaging Ltd. | Trimmed | −75,298 | −$171K | — |
quarter ended December 31, 2025 · filed March 18, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. | Exited | −247,598 | −$8.54M | — |
| Vor Biopharma, Inc. | Exited | −53,732 | −$2.62M | — |
| Vor Biopharma, Inc. | New | +53,732 | +$703K | 0.1% |
| Cvrx, Inc. | Trimmed | −78,569 | −$558K | 5.1% |
| Adicet Bio, Inc. | Exited | −364,472 | −$295K | — |
| Adicet Bio, Inc. | New | +22,779 | +$192K | — |
| Biomx Inc. | Exited | −96,866 | −$50.9K | — |
| Senseonics Holdings, Inc. | Exited | −54,621 | −$23.8K | — |
quarter ended September 30, 2025 · filed March 18, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vor Biopharma, Inc. | Trimmed | −1,020,926 | −$49.7M | 0.5% |
| Rapport Therapeutics, Inc. | Trimmed | −713,534 | −$21.2M | 10.5% |
| Lyell Immunopharma Inc. | New | +54,887 | +$891K | 0.2% |
| Lyell Immunopharma Inc. | Exited | −41,165 | −$368K | — |
quarter ended June 30, 2025 · filed July 22, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lyell Immunopharma Inc. | Trimmed | −782,152 | −$6.99M | 0.1% |
quarter ended March 31, 2025 · filed May 07, 2025
No position changes this quarter.
quarter ended December 31, 2024 · filed February 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lyell Immunopharma Inc. | New | +823,317 | +$527K | 0.1% |
| Clearside Biomedical, Inc. | Exited | −82,481 | −$105K | — |
| Biomx Inc. | Trimmed | −95,455 | −$69.7K | — |
Loading...
